Research Support |

• We are convinced that the true potential of Molecular Imaging can be unleashed only if all stakeholders of the Molecular Imaging join efforts. As an industrial player, IBA considers that it its responsibility to contribute to this initiative by making technical know-how and infrastructures available to you.
• Internally, IBA, partnering with Biotech and pharmaceutical companies, has started already to develop its next generation of tracer, aiming to make PET and Molecular Imaging a major discipline of Healthcare. Our goal being to transform the promises of these disciplines in innovative pharmaceutical solutions for the medical community in Oncology, Cardiology and Neurology.
• To help you contribute to the development of PET, IBA has developed, besides its commercial isotopes production network, a R&D infrastructure which entitles our teams to make available to you a range of new cyclotron products expected to become the key isotopes of tomorrow. Out of the research facilities of Fleurus (IBA, Belgium), Bordeaux (IBA, France) Amsterdam (CVU, Netherlands) and Nantes (Aronnax, France) we have started to make available the most promising nuclides and compounds.

  • I-124
  • Zr-89
  • At-211 (not yet available)
  • Cu-64 (not yet available)
  • FLT
• Additionnally, IBA is willing to associate to a number of research collaborations that pursue the objective giving a new invigoration to Nuclear Medicine and Molecular Imaging.
• Radiochemical offering